The results of the Phase 2 clinical trial of Celltrion’s Corona 19 antibody treatment’Rekironaju’ will be released on the 13th of this month.
Celltrion will participate in the ‘2021 High1 New Drug Development Symposium’ hosted by the Korean Pharmacy Society on the 13th and announce the results of the global clinical phase 2 of Rekkirona.
Earlier, Celltrion applied for conditional approval to the Korean Ministry of Food and Drug Safety after completing Phase 2 of the global clinical trial in Rekirona, but did not disclose detailed clinical data.
An official from Celltrion explained, “The company and the Ministry of Food and Drug Safety have been in close consultation with the early disclosure of clinical data.”
Phase 2 clinical trials were conducted in 327 mild and moderate corona19 patients in Korea, Romania, Spain and the United States.
Celltrion completed the final medication on November 25 last year and applied for conditional approval from the Food and Drug Administration on the 29th of last month.
–
Article reporting and press release provided [email protected]
copyright© tbs. Unauthorized reproduction & redistribution prohibited
